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Abstract
Aim. This study investigates the difference in the incidence of
renal replacement therapy (RRT) between Flanders and the
Netherlands and possible explanations for this difference.
Methods. End-stage renal disease incidence data were ob-
tained from the European Renal Association-European Dial-
ysis and Transplant Association (ERA-EDTA). Additional
sources were the National Institute of Statistics (NIS), the
Central Bureau of Statistics (CBS), the Organisation for
Economic Cooperation and Development (OECD) health
data and the WHO Health For All database (WHO-HFA).
Results. There is remarkable difference in incidence rate of
RRT between Flanders and the Netherlands, with a higher
rate in Flanders. This difference is already present in pa-
tients aged 45–64 years and increases with age, being >2-
fold higher in subjects of 75 years. With respect to the
renal diagnoses leading to need for RRT, a higher share of
especially diabetes mellitus type 2 and renovascular disease
was observed in Flanders. Remarkably, the difference in
incidence rate of RRT is not associated with a difference in
survival on RRT, not even in the elderly, arguing against a
restricted access to RRT in the Netherlands. In the general
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population, the expected number of healthy life years at
birth is lower in Belgium than in the Netherlands, and in
Belgium, the hospital discharge rates for diabetes, acute
myocardial infarction and cerebrovascular accident and
the number of coronary bypass procedures and percutane-
ous coronary interventions per capitum is higher, as is the
prevalence of obesity.
Conclusions. Our data do not support the assumption that the
differences in RRT incidence in the elderly between Flanders
and the Netherlands are due to a more restricted access to RRT
in the Netherlands but may be due to differences in underlying
comorbidity and life style between the two populations.
Keywords: health care system; risk factors; RRT incidence; patient
survival
Introduction
There is a considerable variability in the incidence of renal
replacement therapy (RRT) between and within countries [1–
3]. An example is the difference in RRT incidence that has
been suggested between Flanders—the Dutch-speaking
region of Belgium—and the Netherlands, with a higher in-
cidence rate of RRT in Flanders [4]. This difference would be
unexpected because of the apparent geographic, demographic
and social similarities between these neighbouring regions.
Potential explanations for differences in incidence rate
between neighbouring regions may be either patient, physi-
cian or health care system related. It has been suggested
that physicians in the Netherlands are more restrictive in
referring elderly patients and patients with more co-
morbidity to nephrologists for RRT [5, 6]. If true, a better
survival of patients on RRT is to be expected in the Nether-
lands. Another explanation for a difference in incidence
rates of RRT may be differences in the prevalence of risk
factors for the development of chronic kidney disease
(CKD) in the overall population. For instance, the recent
epidemic of CKD in the USA has been attributed to the
increase in prevalence of obesity and diabetes mellitus [7–
9]. Thirdly, non-medical factors such as differences in
health care system and health care resources may be of
influence. It is even suggested that macroeconomic health
care and renal service organisational factors have a greater
influence on RRT incidence than general population age
and health status factors do [10, 11].
Given these considerations, the aim of this study was to
investigate the difference in incidence rate of RRT between
Flanders and the Netherlands and to explore possible ex-
planations for this difference. To this end, we studied RRT
incidence, patient survival on RRT, prevalence of risk
factors in the general population and health care system
specification in both regions.
Methods
Population and procedure
Data on the socio-demographic characteristics of the general population
for Flanders (and Belgium) were obtained from the National Institute of
Statistics (NIS) and for the Netherlands from the Central Bureau of
Statistics (CBS).
Data on the incidence of RRT and on patient survival on RRT were
obtained from the European Renal Association-European Dialysis and
Transplant Association (ERA-EDTA). The ERA-EDTA Registry is a
European Registry collecting data on RRT via the national and regional
renal registries in Europe. The ERA-EDTA Registry received permission
from the registries of Flanders and the Netherlands to use their data for this
study. These registries cover all the dialysis centres and cover almost
100% of the population in Flanders and the Netherlands.
Data on the prevalence of risk factors for the development of CKD
(diabetes, vascular diseases, overweight and tobacco use) in the general
population are limited. Information on the prevalence of these risk factors
was therefore obtained by studying hospital discharge rates for diabetes
(ICD-10 E10-E14), myocardial infarction (ICD-10 I21-I22) and cerebro-
vascular accidents (ICD-10 I60-I69). These discharge rates include inhos-
pital deaths but exclude day-care admissions and transfers to other care
units within the same institution. Furthermore, information on prevalence
of tobacco consumption, overweight and adiposity is presented as percen-
tages of the total population. According to the World Health Organisation
guidelines, a Body Mass Index >30 kg/m2 is considered to reflect obesity.
Data on discharge rates and on tobacco consumptions and obesity were
obtained from the Organisation for Economic Cooperation and Develop-
ment (OECD) health data [12] and from the WHO Health For All database
(WHO-HFA) [13]. The OECD and WHO-HFA only provided information
for Belgium as a whole and not for Flanders and Wallonia separately. Data
on the health care system in both countries were also obtained from the
WHO-HFA database. All data presented are related to the calendar year
2006, unless stated otherwise.
Statistical analyses
Descriptive statistics were used to compare the characteristics of the gen-
eral population and the incidence rates of RRT between Flanders and the
Netherlands. The incidence of RRT is defined as the number of new
patients that started with RRT [dialysis or (pre-emptive) transplantation]
per year and is expressed as number per million of the population (pmp).
Incidence rates are presented for the overall population as well as for
subgroups based on gender, age and primary renal disease. The incidence
rates for the overall populations are adjusted for age and gender using the
European standard population (EU25, 2000) as the reference population
[14], whereas incidence rates for subgroups are presented in unadjusted
form. To investigate trends over time, we report incidence rates for the
period 1998–2006. Renal diseases leading to need for RRT were defined
according to the ERA-EDTA coding system and classified into eight groups
and the groups ‘unknown’ and ‘missing’. Patient survival (cohort 1998–
2006) was calculated from Day 1 on RRT and the event studied was all-
cause mortality. Unadjusted survival probabilities were calculated using the
Kaplan–Meier method according to Bie et al. [15]. Patients were censored in
the case of recovery of renal function, loss to follow-up or end of follow-up
time (31 December 2006). For the adjusted survival analyses, Cox regres-
sion models were used to compare the survival between patients in the
Netherlands and Flanders adjusting for age, gender and primary renal
disease. Descriptive statistics were also used to compare the prevalence of
risk factors and health care resources in Flanders and the Netherlands.
Results
Characteristics of the general population in 2006
The total population in the Netherlands was in 2006 about
two and a halve times larger than in Flanders. Character-
istics as well as life expectancy of the total population in
Flanders and in the Netherlands were nearly identical, with
the Flemish population being slightly older (Table 1) and
having a lower expectancy for number of healthy life years
at birth than in the Netherlands (Table 2).
Incidence rate of RRT
Change in incidence rate of RRT between 1998 and
2006. Between 1998 and 2006, the annual incidence rate
of RRT increased both in Flanders and in the Netherlands.
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In Flanders, the adjusted RRT incidence rate increased
from 136.7 pmp in 1998 to 167.6 pmp in 2006 and in the
Netherlands from 101.6 in 1998 to 113.3 pmp in 2006.
Thus, over this 9-year period, incidence rates of RRT in-
creased 22.6 and 11.5% in Flanders and the Netherlands,
respectively.
Split by age group, the incidence rate in Flanders and
the Netherlands among patients aged 20–64 years was
nearly the same in 2006 as it was in 1998. The increase
in incidence of RRT was therefore due to the rise in
incidence among patients aged 65–74 years (8.4% in
Flanders and 6.5% in the Netherlands) and especially
in those aged 75 years (89.9% in Flanders and 69.7%
in the Netherlands).
Incidence of RRT by age group and gender in 2006. In
2006, the adjusted incidence rate of RRT in the overall
population was 1.5-fold (167.6/113.3) higher in Flanders
when compared to the Netherlands. Figure 1a illustrates the
unadjusted incidence rate at Day 1 of RRT by age group.
The incidence rate among the age group of 20–44 years
was similar for Flanders and the Netherlands, but in the age
groups of 45–64, 65–74 and 75 years, the incidence rates
were, respectively, 1.3-, 1.4- and 2.3-times higher in Flan-
ders than in the Netherlands.
Figure 1b shows the age-specific incidence rates by gen-
der. The incidence of RRT among women and men 75
years was, respectively, 2.5- and 2.1-times higher in
Flanders than in the Netherlands.
Incidence of RRT by primary renal disease in
2006. Table 3 shows the adjusted incidence rate of
RRT pmp by primary renal diseases for all ages. Nearly,
all primary renal diseases were more frequent in Flanders
than in the Netherlands, but especially diabetes mellitus
type 2 and renal vascular disease as cause of end-stage
renal failure were more common in Flanders when
compared with the Netherlands (2.5- and 2.3-times,
respectively).
The adjusted incidence by primary renal diagnosis per
age group showed the same pattern, with one exception.
The incidence rate for RRT due to diabetes mellitus type II
and renal vascular disease among patients of75 years was
especially high in Flanders (169.6 and 272.3 pmp, respec-
tively) when compared to the Netherlands (36.8 and 89.1
pmp, respectively), indicating a 4.6- and 3.1-times higher
incidence rate in Flanders.
Survival probabilities (cohort 1998–2006)
Figure 2a shows the crude survival probabilities of incident
RRT patients per age group from Day 1 of RRT in Flanders
and the Netherlands over the period 1998–2006. The 90-
day survival rate was almost similar between Flanders and
the Netherlands for all age groups, with in the Netherlands
slightly worse survival. The 1-, 2- and 5-year survival prob-
abilities for patients in the Netherlands were 1.5–6.0%
lower in comparison with Flanders.
The adjusted survival analyses among incident patients
per age group also demonstrate that the 1-, 2- and 5-year
survival probability was slightly lower in the Netherlands
when compared to Flanders, and that this differences
increased with longer observation time (Figure 2b).
Factors that may influence the incidence of RRT
Prevalence of risk factors for CKD in the general
population in 2006. Table 4 shows that hospital dis-
charge rates for diabetes, acute myocardial infarction and
cerebrovascular accident were higher in Belgium than in
the Netherlands. Also, the number of coronary bypass pro-
cedures and percutaneous coronary interventions per ca-
pitum and the percentage of the population with obesity
were higher in Belgium than in the Netherlands. Lifestyle
factors such as fat consumption and the average number of
calories available per person per day are also higher in
Belgium. Only the percentage of the population that used
tobacco was higher in the Netherlands.
Health care resources in 2006. In 2006, Flanders had 27
and the Netherlands 64 dialysis centres. The number of
nephrologists per 1000 of the population was 1.75 higher
in Belgium than in the Netherlands. The number of
physicians per 1000 of the population was similar between
Belgium and the Netherlands, but the number of nurses
was 1.66-times higher in Belgium (Table 5). The number
of hospital and the acute care beds per 1000 inhabitants
were, respectively, 1.47- and 1.43-times higher in
Belgium than in the Netherlands. The total expenditure
on health per capita was $3179 in Belgium and $3320 in
the Netherlands.
Table 1. Characteristics of the general population in Flanders and the
Netherlands in 2006a
Flanders The Netherlands
Inhabitants 6 098 000 16 346 000
Age, %
0–19 years 22.2 24.3
20–64 years 60.0 61.4
651 years 17.8 14.3
Gender, % male 49.3 49.4
Foreign inhabitants, % 5.8 4.2
aSource: NIS and CBS.
Table 2. Life expectancy of the total population Belgium and the
Netherlands in 2006a
Belgium The Netherlands
Life expectancy at birthb
Male 76.61 77.6
Female 82.31 81.9
Life expectancy at age 65b
Male 17.0 16.8
Female 20.6 20.2
Healthy life years at birthc
Male 61.9 63.1
Female 61.7 65.0
aLife expectancy in Flanders is for male and female, respectively, 76.9 and
82.3 years.
bSource: OECD.
cSource: NIS and CBS.
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This study was designed to investigate the difference in
incidence of RRT that has been suggested to exist between
Flanders and the Netherlands and to explore possible
explanations for this difference in RRT incidence. Our data
show that there indeed is a considerable difference in RRT
incidence between Flanders and the Netherlands, even after
adjusting for age and gender. The higher incidence rate in
Flanders was already present in the age group 45–65 years
and increased progressively with age. Among patients aged
75 years, the crude RRT incidence was even more than
twice as high in Flanders as it was in the Netherlands.
Incident RRT patients in Flanders had more often diabetes
mellitus type II and renal vascular disease as cause of end-
stage renal disease (ESRD) leading to RRT. In the general
population, the expected number of healthy life years at
birth was lower in Belgium than in the Netherlands, and
the hospital discharge rates for diabetes, acute myocardial
infarction and cerebrovascular accident and the number of
coronary bypass procedures and percutaneous coronary
interventions per capitum were higher in Belgium, as was
the prevalence of obesity.
What may be the explanation for the higher incidence of
especially elderly patients with diabetic nephropathy or
renal vascular disease entering RRT programmes in






































Fig. 1. (a) Incidence of RRT in Flanders and the Netherlands pmp in 2006 by age group, (unadjusted). (b) Incidence of RRT for male (left) and female
(right) pmp in 2006 by age group (unadjusted). pmp, per million population.
Table 3. Incidence at start of RRT per million population and percentages
by primary renal diagnosis in 2006, adjusted for age and gendera
Flanders The Netherlands
Incidence (pmp) % Incidence (pmp) %
Glomerulonephritis 14.4 8.6 10.4 9.2
Diabetes mellitus
Type 1 5.5 3.3 5.4 4.8
Type 2 31.8 19.0 12.5 11.0
Renal vascular disease 31.5 18.8 13.9 12.3
Hypertension 14.7 8.8 13.3 11.7
Pyelonephritis 10.8 6.4 4.2 3.7
Polycystic kidney disease 8.5 5.1 5.8 5.1
Miscellaneous 34.0 20.3 17.7 15.6
Unknown 16.4 9.8 14.8 13.1
Missing NAb NAb 15.2 13.4
aSource: ERA-EDTA.
bNot applicable.
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suggested that physicians in the Netherlands are more re-
strictive in referring elderly patients and patients with more
co-morbidity to nephrologists for RRT [5, 6]. If true, it
would be expected that patient survival on RRT would
be better in the Netherlands. Importantly, despite the more
favourable characteristics of the RRT population in the
Netherlands, the survival probability of incident RRT pa-
tients was similar or even worse for patients in the Nether-
lands than in Flanders. Our results showed furthermore that
the difference in RRT incidence started already among
patients <65 years of age with a similar pattern of distri-
bution of the primary renal disease categories in all age
groups. These data therefore do not suggest that patient
selection has an important role in explaining the difference
in incidence rates for RRT between Flanders and the
Netherlands. Another study, in which we investigated the
likelihood of referral of primary care physicians and intern-
ists, did also not provide indications for a more restrictive
referral policy in the Netherlands [16].
Differences in health care system and resources might
also explain differences in the incidence of RRT. For in-
stance, it has been suggested that a higher reimbursement
for technical activities (like dialysis) and lower reimburse-
ment for intellectual activities (like prevention and coun-
selling) could limit nephrologists’ interest in preventing the
progression of CKD [17]. A lower gross domestic product
(GDP) per capita and a lower proportion of GDP spent on












90-day survival 1-year survival 2-year survival 5-year survival
20-64 Flanders 20-64 The Netherlands
65-74 Flanders 65-74 The Netherlands












90-day survival 1-year survival 2-year survival 5-year survival
20-64 Flanders 20-64 The Netherlands
65-74 Flanders 65-74 The Netherlands
75+ Flanders 75+ The Netherlands
b
a
Fig. 2. (a) 90-day, 1, 2 and 5-year survival probabilities (cohort 1998–2006): incident RRT patients by age group, unadjusted, from Day 1 of RRT. (b)
90-day, 1, 2 and 5-year survival probabilities (cohort 1998–2006): incident RRT patients by age group, adjusted, from Day 1 of RRT. Adjusted for age,
gender and primary renal disease. Source: ERA-EDTA.
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GDP per capita is higher in the Netherlands, but a lower
proportion of GDP is spent on health care. The number of
nephrologists is higher in Belgium, as is the number of
practising nurses and hospital beds. Other non-medical fac-
tors that have been mentioned to affect incidence of RRT
are health care system related such as financing of renal
care [2, 10] and societal factors such as physician’s referral
behaviour and patients attitude to RRT [6, 19, 20]. As yet,
there is limited understanding whether such factors are of
importance. The international collaboration of nephrolo-
gists, epidemiologists and health economists that recently
started the EVEREST study may help to explain to what
extent the variation in RRT between populations is caused
by such economic and organisational factors [10].
Our data show that the percentage of the general popu-
lation with obesity was higher in Belgium than in the Neth-
erlands. Obesity is an important risk factor for ESRD but
also for diabetes and cardiovascular diseases. In line with
these data, we found that the hospital discharge rate for
diabetes and cardiovascular disease-related admissions
was higher in Belgium than in the Netherlands. This con-
firms the findings of an earlier study in which the general
population in Flanders was found to have a higher preva-
lence of diabetes than in the Netherlands [21]. These data
together with the fact that especially diabetes mellitus type
2 and renal vascular disease were found as causes for the
higher RRT incidence in Flanders lead to the hypothesis
that differences in the prevalence of risk factors for ESRD
explain the difference in RRT incidence rates between
Flanders and the Netherlands. Other epidemiological stud-
ies have provided evidence supporting this hypothesis as
explanation for regional differences in RRT incidence [1, 2,
22]. Another risk factor for ESRD is the proportion of
foreign inhabitants in a country, since in general, these
subjects have a higher chance of CKD due to genetic rea-
sons and/or due to the fact that they predominantly belong
to a lower socio-economic class [23]. However, both the
Flemish and the Netherlands population are relatively
homogeneous with only 5.8 and 4.2% foreign inhabitants,
respectively. Racial differences are therefore not likely to
play a role.
An important strength of this study is that the data on the
incidence of RRT are based on robust and complete data of
national registries covering all centres that offer RRT. This
study has also limitations. Firstly, because a valid registry
of the prevalence of risk factors for ESRD is not available
in Flanders and the Netherlands we had to rely on other
data sources, which included hospital discharge rates and
self-reports. These data are only available for the whole of
Belgium instead of for Flanders specifically. Though the
incidence of RRT in Flanders is similar to that in the other
(French speaking) part of Belgium [24]. It may be, how-
ever, that there are differences in health between these
regions. Secondly, previous studies showed that the ratio
of RRT incidence to CKD prevalence is much higher in
the USA than in Europe [9, 25]. This may be explained by
initiation of RRT at a higher residual Glomerular Filtration
Rate [11] or a higher rate of progression of CKD to ESRD
in the USA [9]. A higher progression rate may be due to, for
instance, less attention for nutritional status, anaemia man-
agement and use of renin–angiotensin system inhibitors
[9]. Unfortunately, information on these variables is not
available for Belgium and the Netherlands on a nationwide
level. Data from the Netherlands Cooperative Study on the
Adequacy of Dialysis (NECOSAD, N ¼ 264) and data
from the Dialysis Outcomes and Practice Patterns Study
(DOPPS, N ¼ 116) for Flanders collected between 2002
and 2004 suggest, however, that RRT is started in these
regions at a similar level [blood creatinine of 6.6 (SD of
2.7) mg/dL in Flanders and 7.9 (SD of 3.2) mg/dL in the
Netherlands (personal communication DOPPS, Els
Boeschoten, Jennifer Bragg-Gresham, and NECOSAD)].
In conclusion, there is remarkable difference in inci-
dence rate of RRT between Flanders and the Netherlands,
with a higher incidence rate in Flanders, which increases
with age. This difference in incidence rate does not result
in a difference in survival, as would be expected in case
patient selection would be present. Our data thus do not
support the assumption that this difference is due to a
more restricted access to RRT in the Netherlands. As
especially diabetes mellitus type 2 and renal vascular
disease leading to need for RRT are high in Belgium
when compared to the Netherlands, and that there is a
higher prevalence of obesity and higher number of cardi-
ovascular intervention and diabetes-related hospital ad-
missions in Belgium, we hypothesize that a difference in
underlying comorbidity and lifestyle between the two





Acute myocardial infarction 154 141
CABG 135.4 58.2
PCI 435.1 144.6
Cerebrovascular accidents 292 195
% of population who are current smokers 22.0 30.8
% of population with obesity 12.7 10.9
Pure alcohol consumption, litres per capita 9.7 10.6
Average number of calories available
per person per day
3675 3218
% of total energy available from fat 39.7 37.5
aSource: OECD and WHO-HFA.
bCABG, coronary artery bypass graft; PCI, percutaneous coronary inter-
vention, per 100 000 population.
Table 5. Health Care Resources in 2006 per 1000 population for the
whole of Belgium and the Netherlandsa
Belgium The Netherlands Ratio
Practising physiciansb 4.0 3.9 1.03
Practising nurses 14.8 8.9 1.66
Nephrologistsc 0.021 0.012 1.75
Hospital beds 6.6 4.5 1.47
Acute care beds 4.3 3.0 1.43
Total expenditure on
health per capita, $
3179 3320 0.96
aSource: WHO-HFA.
bPhysicians includes generalists and specialists.
cData were obtained from the EVEREST study and based on 2003–05.
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populations may explain the observed difference in RRT
incidence.
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